Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE plus PD-1 antibody for unresectable HCC
NCT03782831Phase 2Withdrawn
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2018
- Primary completion
- Dec 2019
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression Free Survival at 12 months. Planned start Dec 2018; status: withdrawn.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03782831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782831.